Has Sunnie Kim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $80,959 in general payments to Sunnie Kim, MD across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sunnie Kim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sunnie Kim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sunnie Kim, MD

Medical Oncology · Aurora, CONPI 1770726465

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,837 of the $80,959 with a category attached, or 87.5%. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 24.4% of the total. 2025 is the largest year on record at $36,534, more than ten times the $126 reported in 2019. Among medical oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$80,959in general payments, 2019–2025

Across 74 payments — averaging $1094.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$20K
Merck$13K
AstraZeneca$11K
Beone Medicines USA, Inc.$11K
Daiichi Sankyo Inc.$8K
Gilead$8K
plus $12K from 8 others

$3,773,037in research payments, 2019–2025

Across 236 payments — averaging $15,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$1.8M
Merck$886K
Seagen Inc.$528K
E.r. Squibb & Sons, L.L.C.$226K
EMD Serono, Inc.$188K
AstraZeneca$86K
plus $78K from 2 others

What the payments were for

Consulting fees$70,83787%
Speaking & faculty fees$1,4252%
Travel & lodging$7,3199%
Food & beverage$1,3602%
Education$180%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	20	$19,758
Merck	6	$12,611
AstraZeneca	8	$10,769
Beone Medicines USA, Inc.	8	$10,555
Daiichi Sankyo Inc.	5	$8,061
Gilead	14	$7,559
Jazz Pharmaceuticals Inc.	1	$3,120
Beigene USA, Inc.	2	$2,400
Eisai Inc.	1	$2,355
Amgen	5	$2,083
Coherus Oncology, Inc.	1	$1,200
EUSA Pharma (US) LLC	1	$225
Array Biopharma Inc	1	$139
Astellas Pharma US Inc	1	$124

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEVIMBRA$10,410
IMFINZI$8,470
Enhertu$3,939
ZIIHERA$3,120
LENVIMA$2,355
LOQTORZI$1,200
Sylvant$225
KEYTRUDA$126

How this compares

$80,959 in reported general payments places this provider in the 95th percentile of 96 medical oncology providers in Colorado.

See all medical oncology providers in Colorado →

Medicare billing

Part B allowed, 2024

$56,916

Medicare patients

128

Services billed

407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LonsurfTrifluridine/Tipiracil Hcl	16	$129,936
CreonLipase/Protease/Amylase	15	$57,278
Morphine Sulfate ErMorphine Sulfate	14	$1,345
Oxycodone Hcl	29	$927
Prochlorperazine Maleate	39	$445
Ondansetron Hcl	35	$361
Lidocaine-PrilocaineLidocaine/Prilocaine	25	$348
LoperamideLoperamide Hcl	15	$227
Mirtazapine	15	$166
Trazodone Hcl	16	$61
Lorazepam	14	$41
Tramadol Hcl	11	$20

Paid to pharmacies, not to this prescriber.

Other medical oncology in Aurora

David CamidgeAurora$648K
Paul BunnAurora$354K
Sapna PatelAurora$186K
Virginia BorgesAurora$68K
Erin SchenkAurora$63K
Karl LewisAurora$62K
Jose PachecoAurora$50K
Leonard GlodeAurora$49K
Robert DoebeleAurora$38K
Christopher LieuAurora$28K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →